Published: August 23, 2021
We found no new information since our published review. Our TOE Grades remain unchanged.
Click on any letter grade below for more info:
Mechanism Grade: D
Preclinical Trials Grade: U
Cases Grade: D
Trials Grade: U
Risks Grade: D
Published: Jul 2017
In conclusion, we find few plausible mechanisms by which components of the EIW regimen might impact ALS progression, and no pre-clinical or clinical evidence to support using this complicated, expensive and potentially risky treatment. Mr. Edney appears to have had very slow ALS progression even before he started his protocol, and there is no convincing evidence that the EIW regimen slowed, stopped or reversed his disease.
Click here to download the complete review.